Does the media refer more to URGN or XENE?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 7 mentions for Urogen Pharma. Xenon Pharmaceuticals' average media sentiment score of 0.67 beat Urogen Pharma's score of 0.24 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or URGN?

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 7 mentions for Urogen Pharma. CRISPR Therapeutics' average media sentiment score of 0.85 beat Urogen Pharma's score of 0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, URGN or CGON?

Urogen Pharma has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 13.19 -$153.49M -$2.75 N/A CG Oncology $4.04M 1,300.30 -$160.99M -$2.33 N/A

Does the media favor URGN or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 10 mentions for CG Oncology and 7 mentions for Urogen Pharma. CG Oncology's average media sentiment score of 0.75 beat Urogen Pharma's score of 0.24 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to APGE or URGN?

In the previous week, Apogee Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for Apogee Therapeutics and 7 mentions for Urogen Pharma. Apogee Therapeutics' average media sentiment score of 0.88 beat Urogen Pharma's score of 0.24 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NNNN or URGN?

Urogen Pharma has a consensus price target of $39.50, suggesting a potential upside of 32.91%. Given Urogen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Urogen Pharma 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has higher valuation & earnings, NNNN or URGN?

Anbio Biotechnology has higher earnings, but lower revenue than Urogen Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 259.33 $6.40M N/A N/A Urogen Pharma $109.79M 13.19 -$153.49M -$2.75 N/A

Is NNNN or URGN more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Urogen Pharma -94.83% N/A -62.85%

Urogen Pharma (URGN) Competitors

$29.72 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$29.74 +0.03 (+0.08%)

As of 06/12/2026 07:34 PM Eastern

Compare

URGN vs. XENE, CRSP, CGON, APGE, and NNNN

Should you buy Urogen Pharma stock or one of its competitors? MarketBeat compares Urogen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Urogen Pharma include Xenon Pharmaceuticals (XENE), CRISPR Therapeutics (CRSP), CG Oncology (CGON), Apogee Therapeutics (APGE), and Anbio Biotechnology (NNNN). These companies are all part of the "pharmaceutical products" industry.

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Urogen Pharma currently has a consensus price target of $39.50, suggesting a potential upside of 32.91%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 48.18%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Urogen Pharma has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	13.19	-$153.49M	-$2.75	N/A
Xenon Pharmaceuticals	$7.50M	671.53	-$345.91M	-$4.70	N/A

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Urogen Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 7 mentions for Urogen Pharma. Xenon Pharmaceuticals' average media sentiment score of 0.67 beat Urogen Pharma's score of 0.24 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Urogen Pharma on 10 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 7 mentions for Urogen Pharma. CRISPR Therapeutics' average media sentiment score of 0.85 beat Urogen Pharma's score of 0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Urogen Pharma has higher revenue and earnings than CRISPR Therapeutics. Urogen Pharma is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,368.44	-$581.60M	-$6.22	N/A
Urogen Pharma	$109.79M	13.19	-$153.49M	-$2.75	N/A

CRISPR Therapeutics presently has a consensus price target of $67.78, suggesting a potential upside of 36.10%. Urogen Pharma has a consensus price target of $39.50, suggesting a potential upside of 32.91%. Given CRISPR Therapeutics' higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Urogen Pharma has a net margin of -94.83% compared to CRISPR Therapeutics' net margin of -13,856.54%. Urogen Pharma's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Urogen Pharma	-94.83%	N/A	-62.85%

Summary

CRISPR Therapeutics and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to CG Oncology?

Urogen Pharma (NASDAQ:URGN) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Urogen Pharma has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	13.19	-$153.49M	-$2.75	N/A
CG Oncology	$4.04M	1,300.30	-$160.99M	-$2.33	N/A

CG Oncology has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
CG Oncology	N/A	-23.33%	-22.24%

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Urogen Pharma currently has a consensus price target of $39.50, indicating a potential upside of 32.91%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 37.22%. Given CG Oncology's higher probable upside, analysts plainly believe CG Oncology is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 10 mentions for CG Oncology and 7 mentions for Urogen Pharma. CG Oncology's average media sentiment score of 0.75 beat Urogen Pharma's score of 0.24 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Urogen Pharma has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Summary

Urogen Pharma and CG Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Apogee Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Urogen Pharma	-94.83%	N/A	-62.85%

In the previous week, Apogee Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for Apogee Therapeutics and 7 mentions for Urogen Pharma. Apogee Therapeutics' average media sentiment score of 0.88 beat Urogen Pharma's score of 0.24 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics presently has a consensus price target of $114.56, indicating a potential upside of 29.70%. Urogen Pharma has a consensus price target of $39.50, indicating a potential upside of 32.91%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Urogen Pharma is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Urogen Pharma has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Urogen Pharma	$109.79M	13.19	-$153.49M	-$2.75	N/A

Apogee Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Urogen Pharma beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Urogen Pharma (NASDAQ:URGN) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

In the previous week, Urogen Pharma had 6 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Urogen Pharma and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.89 beat Urogen Pharma's score of 0.24 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Urogen Pharma	Neutral

Urogen Pharma has a consensus price target of $39.50, suggesting a potential upside of 32.91%. Given Urogen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Anbio Biotechnology has higher earnings, but lower revenue than Urogen Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	259.33	$6.40M	N/A	N/A
Urogen Pharma	$109.79M	13.19	-$153.49M	-$2.75	N/A

Anbio Biotechnology has a beta of 4.4, suggesting that its stock price is 340% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

91.3% of Urogen Pharma shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Urogen Pharma	-94.83%	N/A	-62.85%

Summary

Urogen Pharma beats Anbio Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.45B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-10.81	20.00	23.99	24.42
Price / Sales	13.19	306.82	513.41	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-13.21	8.32	10.73	6.82
Net Income	-$153.49M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.06%	1.84%	0.59%	1.17%
1 Month Performance	3.27%	-0.04%	1.54%	3.16%
1 Year Performance	147.05%	44.82%	25.42%	30.58%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	2.9035 of 5 stars	$29.72 flat	$39.50 +32.9%	+147.0%	$1.45B	$109.79M	N/A	200
XENE Xenon Pharmaceuticals	3.5823 of 5 stars	$53.46 +2.2%	$77.20 +44.4%	+59.0%	$5.06B	$7.50M	N/A	210
CRSP CRISPR Therapeutics	3.51 of 5 stars	$52.08 +0.1%	$65.47 +25.7%	+20.4%	$5.02B	$3.51M	N/A	460	Analyst Forecast
CGON CG Oncology	2.7917 of 5 stars	$54.48 -1.9%	$81.73 +50.0%	+130.3%	$4.90B	$4.04M	N/A	61
APGE Apogee Therapeutics	3.2757 of 5 stars	$84.19 +7.0%	$113.63 +35.0%	+98.6%	$4.87B	N/A	N/A	91	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. XENE, CRSP, CGON, APGE, and NNNN

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Summary

How does Urogen Pharma compare to CRISPR Therapeutics?

Summary

How does Urogen Pharma compare to CG Oncology?

Summary

How does Urogen Pharma compare to Apogee Therapeutics?

Summary

How does Urogen Pharma compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. XENE, CRSP, CGON, APGE, and NNNN

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Is URGN or XENE more profitable?

Do analysts recommend URGN or XENE?

Which has better earnings and valuation, URGN or XENE?

Do insiders & institutionals hold more shares of URGN or XENE?

Which has more risk and volatility, URGN or XENE?

Does the media refer more to URGN or XENE?

Summary

How does Urogen Pharma compare to CRISPR Therapeutics?

Do institutionals and insiders hold more shares of CRSP or URGN?

Does the media refer more to CRSP or URGN?

Which has better valuation & earnings, CRSP or URGN?

Do analysts prefer CRSP or URGN?

Which has more volatility and risk, CRSP or URGN?

Is CRSP or URGN more profitable?

Summary

How does Urogen Pharma compare to CG Oncology?

Which has higher valuation & earnings, URGN or CGON?

Is URGN or CGON more profitable?

Do institutionals and insiders believe in URGN or CGON?

Do analysts prefer URGN or CGON?

Does the media favor URGN or CGON?

Which has more risk and volatility, URGN or CGON?

Summary

How does Urogen Pharma compare to Apogee Therapeutics?

Is APGE or URGN more profitable?

Does the media refer more to APGE or URGN?

Do analysts rate APGE or URGN?

Which has better valuation & earnings, APGE or URGN?

Which has more risk and volatility, APGE or URGN?

Do insiders and institutionals believe in APGE or URGN?

Summary

How does Urogen Pharma compare to Anbio Biotechnology?

Does the media refer more to NNNN or URGN?

Do analysts recommend NNNN or URGN?

Which has higher valuation & earnings, NNNN or URGN?

Which has more volatility and risk, NNNN or URGN?

Do institutionals and insiders believe in NNNN or URGN?

Is NNNN or URGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools